COVAXIN (Bio-Safety Level 3)

COVAXIN (Bio-Safety Level 3)

COVAXIN (Bio-Safety Level 3)

COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.

The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials will commence across India from July 2020.

source: https://www.bharatbiotech.com/covaxin.html